Novo Nordisk’s mAb for MACE risk reduction fails in Phase III trial
Phase 3negativeziltivekimabNegative
AI Analysis
Summary
Novo Nordisk's ziltivekimab, a monoclonal antibody candidate, failed its Phase III trial for MACE risk reduction. The company continues to investigate the drug in separate studies for heart failure and acute myocardial infarction.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
Phase III trial failed to meet primary endpoint for MACE risk reduction
Importance:8/10
Sentiment:
-0.80
Phase 3 failuremonoclonal antibodycardiovascularMACEheart failureacute myocardial infarction
Related Companies
Read the original article
Published by Clinical Trials Arena on July 31, 2026 2:20 PM